Effectiveness of increasing alcohol excise taxes in the management of alcohol-associated liver disease in China

Feiyu ZHANG; Peng XIAO; Yali LIU; Tao LIU; Yanhang GAO

doi:10.3969/j.issn.1001-5256.2023.07.027

Volume 39 Issue 7

Jul. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(7): 1703-1707

PDF( 1707 KB)

Effectiveness of increasing alcohol excise taxes in the management of alcohol-associated liver disease in China

DOI: 10.3969/j.issn.1001-5256.2023.07.027

Department of Hepatology, The First Hospital of Jilin University, Changchun 130021, China

Research funding:

National Natural Science Foundation of China (81972265);

National Natural Science Foundation of China (82170602);

National Natural Science Foundation of Jilin Province (20200201324JC);

Project for Health Talents of Jilin Province (JLSWSRCZX 2021-079)

More Information

Corresponding author: GAO Yanhang, yanhang@mail.jlu.edu.cn (ORCID: 0000-0002-7248-8290)
Received Date: 2022-10-23
Accepted Date: 2022-11-25
Published Date: 2023-07-20

Abstract

Abstract

Increasing alcohol excise taxes has been confirmed by the World Health Organization as the most cost-effective public policy for reducing alcohol consumption at the population level. In recent years, studies in foreign countries have believed that increasing alcohol excise taxes can improve the burden of alcohol-associated liver disease (ALD), but it is still unclear whether this policy is applicable to ALD management in China. Therefore, with reference to related research evidence in China and globally, this article analyzes the key factors influencing the effectiveness of the policy of increasing alcohol excise taxes from the perspective of ALD management in China, including tax shifting, price elasticity of demand, and unrecorded alcohol, and introduces other public policies that help curb ALD. We think that increasing alcohol excise taxes is currently a useful but not effective policy for improving the burden of ALD in China.
- Liver Diseases, Alcoholic,
- Alcohol Drinking,
- Excise tax

FullText(HTML)

References(38)

References

[1]	World Health Organization. World health statistics 2022: monitoring health for the SDGs, sustainable development goals[EB/OL]. (2022-05-19)[2022-10-1]. https://www.who.int/publications/i/item/9789240051157.
[2]	World Health Organization. Global status report on alcohol and health 2018[EB/OL]. (2018-09-27)[2022-10-1]. https://www.who.int/publications/i/item/9789241565639.
[3]	XU H, XIAO P, ZHANG F, et al. Epidemic characteristics of alcohol-related liver disease in Asia from 2000 to 2020: A systematic review and meta-analysis[J]. Liver Int, 2022, 42(9): 1991-1998. DOI: 10.1111/liv.15312.
[4]	World Health Organization. Global strategy to reduce the harmful use of alcohol[EB/OL]. (2010-05-31)[2022-10-1]. https://www.who.int/publications/i/item/9789241599931.
[5]	ASRANI SK, MELLINGER J, ARAB JP, et al. Reducing the global burden of alcohol-associated liver disease: A blueprint for action[J]. Hepatology, 2021, 73(5): 2039-2050. DOI: 10.1002/hep.31583.
[6]	PONICKI WR, GRUENEWALD PJ. The impact of alcohol taxation on liver cirrhosis mortality[J]. J Stud Alcohol, 2006, 67(6): 934-938. DOI: 10.15288/jsa.2006.67.934.
[7]	SHEN NT, BRAY J, WAHID NA, et al. Evaluation of alcohol taxes as a public health opportunity to reduce liver transplant listings for alcohol-related liver disease[J]. Alcohol Clin Exp Res, 2020, 44(11): 2307-2315. DOI: 10.1111/acer.14454.
[8]	WILSON LB, PRYCE R, ANGUS C, et al. The effect of alcohol tax changes on retail prices: how do on-trade alcohol retailers pass through tax changes to consumers?[J]. Eur J Health Econ, 2021, 22(3): 381-392. DOI: 10.1007/s10198-020-01261-1.
[9]	ALLY AK, MENG Y, CHAKRABORTY R, et al. Alcohol tax pass-through across the product and price range: do retailers treat cheap alcohol differently?[J]. Addiction, 2014, 109(12): 1994-2002. DOI: 10.1111/add.12590.
[10]	PARIKH ND, CHUNG GS, MELLINGER J, et al. Alcohol policies and alcohol-related liver disease mortality[J]. Gastroenterology, 2021, 161(1): 350-352. DOI: 10.1053/j.gastro.2021.03.031.
[11]	FEI MQ, LIU J, HUANG J. Discussion on liquor consumption taxation in China[J]. Tax Res, 2021(9): 37-42. DOI: 10.19376/j.cnki.cn11-1011/f.2021.09.006. 费茂清, 刘佳, 黄江. 关于我国白酒消费税的探讨[J]. 税务研究, 2021(9): 37-42. DOI: 10.19376/j.cnki.cn11-1011/f.2021.09.006.
[12]	WAGENAAR AC, SALOIS MJ, KOMRO KA. Effects of beverage alcohol price and tax levels on drinking: a meta-analysis of 1003 estimates from 112 studies[J]. Addiction, 2009, 104(2): 179-190. DOI: 10.1111/j.1360-0443.2008.02438.x.
[13]	TIAN G, LIU F. Is the demand for alcoholic beverages in developing countries sensitive to price? Evidence from China[J]. Int J Environ Res Public Health, 2011, 8(6): 2124-2131. DOI: 10.3390/ijerph8062124.
[14]	ZHAO Z, WANG L, ZHANG M, et al. Geographic distribution of alcohol use among Chinese adults - China, 2015[J]. China CDC Wkly, 2020, 2(7): 98-103.
[15]	SHI Y. Three essays on economics of health behavior in China[CD]. Ann Arbor: The Pardee RAND Graduate School, 2011.
[16]	WANG H, MA L, YIN Q, et al. Prevalence of alcoholic liver disease and its association with socioeconomic status in north-eastern China[J]. Alcohol Clin Exp Res, 2014, 38(4): 1035-1041. DOI: 10.1111/acer.12321.
[17]	EWING SW, SAKHARDANDE A, BLAKEMORE SJ. The effect of alcohol consumption on the adolescent brain: A systematic review of MRI and fMRI studies of alcohol-using youth[J]. Neuroimage Clin, 2014, 5: 420-437. DOI: 10.1016/j.nicl.2014.06.011.
[18]	WALLER R, MURRAY L, SHAW DS, et al. Accelerated alcohol use across adolescence predicts early adult symptoms of alcohol use disorder via reward-related neural function[J]. Psychol Med, 2019, 49(4): 675-684. DOI: 10.1017/S003329171800137X.
[19]	GALLET CA. The demand for alcohol: a meta-analysis of elasticities[J]. Aust J Agric Res Econ, 2007, 51(2): 121-135. DOI: 10.1111/j.1467-8489.2007.00365.x.
[20]	MEIER PS, PURSHOUSE R, BRENNAN A. Policy options for alcohol price regulation: the importance of modelling population heterogeneity[J]. Addiction, 2010, 105(3): 383-393. DOI: 10.1111/j.1360-0443.2009.02721.x.
[21]	BLACK H, GILL J, CHICK J. The price of a drink: levels of consumption and price paid per unit of alcohol by Edinburgh's ill drinkers with a comparison to wider alcohol sales in Scotland[J]. Addiction, 2011, 106(4): 729-736. DOI: 10.1111/j.1360-0443.2010.03225.x.
[22]	AYYAGARI P, DEB P, FLETCHER J, et al. Understanding heterogeneity in price elasticities in the demand for alcohol for older individuals[J]. Health Econ, 2013, 22(1): 89-105. DOI: 10.1002/hec.1817.
[23]	NELSON JP. Gender differences in alcohol demand: a systematic review of the role of prices and taxes[J]. Health Econ, 2014, 23(10): 1260-1280. DOI: 10.1002/hec.2974.
[24]	MÄKELÄ P, PALJÄRVI T. Do consequences of a given pattern of drinking vary by socioeconomic status? A mortality and hospitalisation follow-up for alcohol-related causes of the Finnish Drinking Habits Surveys[J]. J Epidemiol Community Health, 2008, 62(8): 728-733. DOI: 10.1136/jech.2007.065672.
[25]	PROBST C, KILIAN C, SANCHEZ S, et al. The role of alcohol use and drinking patterns in socioeconomic inequalities in mortality: a systematic review[J]. Lancet Public Health, 2020, 5(6): e324-324e332. DOI: 10.1016/S2468-2667(20)30052-9.
[26]	SASSI F, BELLONI A, MIRELMAN AJ, et al. Equity impacts of price policies to promote healthy behaviours[J]. Lancet, 2018, 391(10134): 2059-2070. DOI: 10.1016/S0140-6736(18)30531-2.
[27]	LACHENMEIER DW, GMEL G, REHM J. Unrecorded alcohol consumption[J]. Alcohol: science, policy, and public health, 2013: 132-142.
[28]	NEWMAN IM, QIAN L, TAMRAKAR N, et al. Chemical composition and safety of unrecorded grain alcohol (Bai Jiu) samples from three provinces in China[J]. Int J Environ Res Public Health, 2018, 15(12): 2710. DOI: 10.3390/ijerph15122710.
[29]	WEI S, YIN P, NEWMAN IM, et al. Comparison of patterns of use of unrecorded and recorded spirits: Survey of adult drinkers in rural central China[J]. Int J Environ Res Public Health, 2017, 14(10): 1099. DOI: 10.3390/ijerph14101099.
[30]	World Health Organization. Unrecorded alcohol: what the evidence tells us[EB/OL]. (2022-03-21)[2022-10-1]. https://www.who.int/publications/i/item/9789240044463.
[31]	NEWMAN I, QIAN L, TAMRAKAR N, et al. Composition of unrecorded distilled alcohol (bai jiu) produced in small rural factories in central China[J]. Alcohol Clin Exp Res, 2017, 41(1): 207-215. DOI: 10.1111/acer.13280.
[32]	QIAN L, NEWMAN IM, XIONG W, et al. Traditional grain alcohol (bai jiu, [Symbol: see text]) production and use in rural central China: implications for public health[J]. BMC Public Health, 2015, 15: 1261. DOI: 10.1186/s12889-015-2594-4.
[33]	LACHENMEIER DW. Reducing harm from alcohol: what about unrecorded products?[J]. Lancet, 2009, 374(9694): 977. DOI: 10.1016/S0140-6736(09)61661-5.
[34]	NEMTSOV AV. Mortality in Russia in light of the in alcohol consumption[J]. Demographic review, 2015, 2(4): 111-135.
[35]	DING L, SONG B, WU C, et al. Alcohol use in China: Unrecorded and recorded bai jiu in three rural regions[J]. Int J Environ Res Public Health, 2021, 19(1): 405. DOI: 10.3390/ijerph19010405.
[36]	ANDERSON P, O'DONNELL A, KANER E, et al. Impact of minimum unit pricing on alcohol purchases in Scotland and Wales: controlled interrupted time series analyses[J]. Lancet Public Health, 2021, 6(8): e557-e565. DOI: 10.1016/S2468-2667(21)00052-9.
[37]	LEAL-LÓPEZ E, MORENO-MALDONADO C, INCHLEY J, et al. Association of alcohol control policies with adolescent alcohol consumption and with social inequality in adolescent alcohol consumption: A multilevel study in 33 countries and regions[J]. Int J Drug Policy, 2020, 84: 102854. DOI: 10.1016/j.drugpo.2020.102854.
[38]	AVANCEÑA A, MILLER N, UTTAL SE, et al. Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis[J]. J Hepatol, 2021, 74(6): 1286-1294. DOI: 10.1016/j.jhep.2020.12.004.

Relative Articles

[1]	Zhuoga RENZENG, Kangjie YANG, Yongliang LU, Zhixin WANG, Haijiu WANG. Research advances in neutrophil extracellular traps and liver diseases[J]. Journal of Clinical Hepatology, 2024, 40(3): 639-643. doi: 10.12449/JCH240334
[2]	Mingqiang ZHU, Xing XIE, Qicheng LIAO, Xiao HE, Youming DING, Xiaohua WANG. Mechanism of cuproptosis and its role in liver diseases[J]. Journal of Clinical Hepatology, 2024, 40(11): 2332-2337. doi: 10.12449/JCH241131
[3]	Guiqiang WANG. Application and prospect of cell therapy in clinical treatment of liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(5): 1001-1003. doi: 10.3969/j.issn.1001-5256.2023.05.001
[4]	Zhuoran WANG, Bing ZHU, Limei YU, Shaoli YOU. Role of stem cell-derived exosomes in treatment of liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(3): 699-706. doi: 10.3969/j.issn.1001-5256.2023.03.034
[5]	Feiyan LI, Minggang WANG, Dewen MAO, Xiongbin GUI. Role of gasdermin D in the pathological progression of liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(3): 707-712. doi: 10.3969/j.issn.1001-5256.2023.03.035
[6]	Wenshang CHEN, Jijin ZHU, Shilai LI. Role of thymic stromal lymphopoietin in liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(5): 1175-1178. doi: 10.3969/j.issn.1001-5256.2022.05.042
[7]	Weiyu CHEN, Faming SHU, Han WANG, Yanggang CAO, Jin HU, Dewen MAO. Role of the cytochrome P450 family in metabolic-associated liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(9): 2182-2187. doi: 10.3969/j.issn.1001-5256.2022.09.045
[8]	Rui CHEN, Zhixin WANG, Haining FAN, Haijiu WANG. Research advances in the role of lymphocyte activation gene-3 in liver-related diseases[J]. Journal of Clinical Hepatology, 2021, 37(4): 977-981. doi: 10.3969/j.issn.1001-5256.2021.04.056
[9]	Lihui ZHANG, Minghao LIU, Wenxia ZHAO. Role of lipotoxicity in the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(2): 463-466. doi: 10.3969/j.issn.1001-5256.2021.02.045
[10]	Feiyu ZHANG, ADILA·Yakepu, Jinming ZHAO, Yanhang GAO. Mechanism of ferroptosis and its role in liver diseases[J]. Journal of Clinical Hepatology, 2021, 37(6): 1454-1458. doi: 10.3969/j.issn.1001-5256.2021.06.049
[11]	XU LiJun, AN XiuQin, LI Yue, LIU JinChun. Research advances in the role of myeloid-derived suppressor cells in liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(12): 2851-2855. doi: 10.3969/j.issn.1001-5256.2020.12.045
[12]	XIAO WeiSong, LE YingYu, ZENG ShengLan, TAN XiaoBin, WU Cong, YA ChengYu, MAO DeWen. Role of pyroptosis in liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(12): 2847-2850. doi: 10.3969/j.issn.1001-5256.2020.12.044
[13]	Wang ShaSha, Hua Fang, Jiao YongGeng, Qin ErYun, Zhi YiXiao, Pang MengYuan, Xu HongQin, Chi XiuMei, Niu JunQi, Hua Rui. Serum level of ceruloplasmin in patients with different liver diseases in Jilin,China[J]. Journal of Clinical Hepatology, 2020, 36(9): 2025-2029. doi: 10.3969/j.issn.1001-5256.2020.09.023
[14]	Chen ShuRu, Chong YuTian, Li XinHua. Pathogenic mechanism and clinical diagnosis of hereditary abnormal copper metabolism[J]. Journal of Clinical Hepatology, 2019, 35(8): 1667-1672. doi: 10.3969/j.issn.1001-5256.2019.08.003
[15]	Yu PengFei, Wu Qiao, Duan ZhongPing, Chen Yu. Research advances in the mechanism of drug-induced liver injury due to paracetamol[J]. Journal of Clinical Hepatology, 2019, 35(9): 2108-2112. doi: 10.3969/j.issn.1001-5256.2019.09.050
[16]	Chen Xiang, Wen DiGuang, You Yu, Gong JianPing. Role and mechanism of ferroptosis in treatment of liver cancer with sorafenib[J]. Journal of Clinical Hepatology, 2019, 35(10): 2316-2319. doi: 10.3969/j.issn.1001-5256.2019.10.040
[17]	Bao SuXia, Zheng JianMing, Shi GuangFeng. Research progress in association between interleukin-23 and liver diseases[J]. Journal of Clinical Hepatology, 2016, 32(2): 393-396. doi: 10.3969/j.issn.1001-5256.2016.02.044
[18]	Lu: XinPing, Wu Jing, Chen JingTao. Application of antibody preparation technology based on single B lymphocytes in liver diseases[J]. Journal of Clinical Hepatology, 2015, 31(12): 2104-2109. doi: 10.3969/j.issn.1001-5256.2015.12.028
[19]	Huang LanYu, Xu LieMing. Relationship between liver diseases and autophagy[J]. Journal of Clinical Hepatology, 2014, 30(2): 186-188. doi: 10.3969/j.issn.1001-5256.2014.02.022
[20]	Liu GuoWang, Cao WuKui. Application of stem cells in liver disease treatment[J]. Journal of Clinical Hepatology, 2011, 27(9): 999-1002.

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	郭新华，王佳慧，段雪琳，彭岳，赵铁建，郑洋，赵斌. 金属离子代谢：慢性肝病中医药防治新思路. 临床肝胆病杂志. 2024(07): 1498-1504 . 本站查看
2.	董昌君，张先林. 铜死亡在肝细胞癌发病机制中的研究进展. 中国普通外科杂志. 2024(07): 1172-1179 .
3.	刘诗卉，李冬冬，张宏坤，刘传苗，吴执竞，赵文. 细胞死亡在NAFLD发生发展中的研究进展. 齐齐哈尔医学院学报. 2024(16): 1578-1582 .
4.	朱明强，谢星，廖启成，何晓，丁佑铭，王小华. 铜死亡的发生机制及在肝脏疾病中的作用. 临床肝胆病杂志. 2024(11): 2332-2337 . 本站查看

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (352) PDF downloads(36)

Effectiveness of increasing alcohol excise taxes in the management of alcohol-associated liver disease in China

DOI: 10.3969/j.issn.1001-5256.2023.07.027